idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
idw - Informationsdienst
Wissenschaft
Chimeric antigen receptor (CAR) T-cell therapy is based on engineered immune cells that find and destroy cancer cells. However, sometimes these cells also attack healthy tissues, causing side effects. An international team of researchers, including LIT scientists Dr. Leo Scheller, Dr. Markus Barden, and Prof. Hinrich Abken, has now developed a system to control T-cell binding to other cells by an approved small molecule drug.
Researchers at the Leibniz Institute for Immunotherapy (LIT), Ecole polytechnique fédérale de Lausanne (EPFL), ETH Zürich, and Lausanne University have developed a system to make CAR T-cell therapies safer and more controllable. Published in Nature Chemical Biology, the new work introduces DROP-CAR (Drug-Regulated Off-switch PPI CAR) systems to remotely control CAR T-cell activity using venetoclax, a clinically approved drug already in use for blood cancers. This technology can precisely modulate therapeutic function of CAR T cells, if adverse effects emerge.
"CAR T-cell therapy has revolutionized treatment for certain blood cancers, but progress for many other tumors is held back by safety concerns," explains Dr. Leo Scheller, lead author and head of the research group Structural Biochemistry at the LIT. “New tools like the DROP-CAR take steps towards bringing new treatments to the clinic that might otherwise be too risky."
Control Through Protein-Protein Interactions
A CAR contains an outer part sticking out of the T cell that recognizes cancerous target cells, and an intracellular part that signals to the T cell to kill, once activated. However, sometimes healthy cells are mistakenly targeted by the same mechanism. The DROP-CAR splits the two receptor parts into two separate components. Adding the drug venetoclax causes the outer part to fall off, prohibiting T cells from binding to other cells in the first place. This method is expected to increase safety of potential CAR T-cell therapies.
About the Leibniz Institute for Immunotherapy (LIT)
The LIT is an institute within the Leibniz Association located in Regensburg, Germany. Our mission is to develop innovative therapies for the treatment of cancer, autoimmunity, and chronic inflammation. By reprogramming immune cells through synthetic and pharmacological strategies, we build cells that save lives.
Dr. Leo Scheller
Head of the Structural Biochemistry Group
LIT – Leibniz Institute for Immunotherapy
Franz-Josef-Strauß-Allee 11
93053 Regensburg
Email: Leo.scheller@lit.eu
Scheller, L., Giordano Attianese, G.M.P., Castellanos-Rueda, R. et al. Drug-controlled CAR T cells through the regulation of cell–cell interactions. Nat Chem Biol (2026).
https://doi.org/10.1038/s41589-026-02152-x
Schematic illustration of a DROP-CAR
Copyright: Leo Scheller
Criteria of this press release:
Journalists, Scientists and scholars
Biology, Medicine
transregional, national
Research results
English
You can combine search terms with and, or and/or not, e.g. Philo not logy.
You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).
Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.
You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).
If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).
